Effect of Electroacupuncture on SAP With MODS

Sponsor
Jianbo Yu (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04813510
Collaborator
(none)
110
2
18.2

Study Details

Study Description

Brief Summary

  1. Title: Effect of Electroacupuncture on Severe Acute Pancreatitis with Multiple Organ Disfunction Syndrome patients: A Randomized Clinical Trial

  2. Research center: single center

  3. Design of the research: A randomized, double-blind and parallel controlled study

  4. Object of the research: The patients over 18 years that met the criteria of SAP and with more than 2 organs failure.

  5. Sample size of the research: A total of 220patients,110 cases in each group

  6. Interventions: The acupuncture points for electroacupuncture are Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) points . Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at above points once a day for seven days. After"Deqi",electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of treatment. Participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no "Deqi" without actual current output.

  7. Aim of the research: To investigate the effect of electroacupuncture on Severe Acute Pancreatitis with Multiple Organ Disfunction Syndrome.

  8. Outcome #Primary outcomes: All-cause 28-day mortality. Secondary outcomes: Duration of organ failure; The incidence of pancreatic necrotic tissue infection; Time for enteral nutrition to reach the standard (30kcal/kg); Mechanical ventilation time; Length of hospital stay

  9. The estimated duration of the study#2 years.

Condition or Disease Intervention/Treatment Phase
  • Device: electroacupuncture treatment
  • Device: sham electroacupuncture treatment
N/A

Detailed Description

This study is a randomized, double-blinded, placebo controlled and long-term follow-up design. In this study, Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) were selected for electroacupuncture treatment, accompanied with evaluating the effects on 28-day mortality in SAP patients with MODS, as well as the duration of organ failure, the incidence of pancreatic necrotic tissue infection and length of hospital stay . To clarify the effect of electroacupuncture on SAP patients with MODS is of great significance to the clinical applications and popularization of traditional acupuncture treatment across the world.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Effect of Electroacupuncture on SAP With MODS: a Prospective, Double-blind, Randomized Controlled Trial
Anticipated Study Start Date :
Dec 22, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: electroacupuncture treatment

Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. After"Deqi",electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment.

Device: electroacupuncture treatment
Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. After"Deqi", electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment.

Sham Comparator: sham electroacupuncture treatment

Participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no "Deqi" without actual current output.

Device: sham electroacupuncture treatment
Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no "Deqi" without actual current output, and retained the needle for the same time as treatment group

Outcome Measures

Primary Outcome Measures

  1. All-cause 28-day mortality [1-2year]

    All reasons (such as infection, hemorrhage) caused the mortality during the first 28 days after treatments

Secondary Outcome Measures

  1. Duration of organ failure [an average of 1-2 year]

    The time of organ failure recovered

  2. The incidence of pancreatic necrotic tissue infection [up to one year]

    The incidence of pancreatic necrotic tissue infection

  3. Duration of mechanical ventilation in patients with endotracheal intubation in ICU [an average of 1 year]

    Duration of mechanical ventilation in patients with endotracheal intubation in ICU

  4. Length of stay in hospital [24 months]

    ICU stay time and hospitalization time

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Meet the diagnosis of severe acute pancreatitis (Atlanta diagnostic criteria), within 1 week of onset

  2. Combine 2 or more organ failures at the same time, and the duration is greater than 48h

  3. Age ≥18 years old;

  4. Obtain informed consent.

Exclusion Criteria:
  1. Pregnancy pancreatitis;

  2. Patients who have undergone percutaneous puncture or surgical drainage before admission, and have undergone surgical decompression due to early abdominal hypertension;

  3. Patients with a history of chronic organ dysfunction (such as uremia, COPD, liver cirrhosis, heart failure, etc.).

  4. Those who have a medical history of acupuncture and moxibustion or are not sensitive to acupuncture and moxibustion.

  5. Those who refuse to participate in the research

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Jianbo Yu

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jianbo Yu, Department of Anesthesiology, Director, Chief physician, Professor, Doctoral tutor, Tianjin Nankai Hospital
ClinicalTrials.gov Identifier:
NCT04813510
Other Study ID Numbers:
  • EA-SAP-202103
First Posted:
Mar 24, 2021
Last Update Posted:
Dec 22, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jianbo Yu, Department of Anesthesiology, Director, Chief physician, Professor, Doctoral tutor, Tianjin Nankai Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2021